Histamine Receptor Signaling in CNS Autoimmune Disease
Histamine Receptor Signaling in CNS Autoimmune Disease
批准号:
8015316
负责人:
CORY TEUSCHER
金额:
$61.39万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-19 至 2012-12-31
关键词:
1,2-diacylglycerolAmino AcidsAntigen-Presenting CellsAutoimmune ProcessBlood - brain barrier anatomyCD4 Positive T LymphocytesCNS autoimmune diseaseCentral Nervous System DiseasesChronicDataDevelopmentDiglyceridesDistalDrug usageEpidemiologyExperimental Autoimmune EncephalomyelitisFreund&aposs AdjuvantG-Protein-Coupled ReceptorsGenesHRH2 geneHistamineHistamine H1 ReceptorsHistamine H2 ReceptorsHistamine H3 ReceptorsHistamine ReceptorHistidine DecarboxylaseHybridsHydroxyzineImmuneImmune responseInflammation MediatorsInflammatoryInositolInterleukin-4LengthMAP2K6 geneMediatingMemoryModelingModificationMonoclonal AntibodiesMultiple SclerosisMusNamesNeuraxisPathogenesisPatientsPeptidesPermeabilityPertussis ToxinPharmacologic SubstancePlayPredispositionPrincipal InvestigatorProductionPublishingReceptor SignalingRegulationResearchResource SharingReverse Transcriptase Polymerase Chain ReactionRiskRoleSeveritiesSeverity of illnessSignal PathwaySignal TransductionSpinal CordT cell responseT memory cellT-Cell ReceptorT-LymphocyteTNF geneTestingTimeTranscriptTransgenic MiceTransgenic OrganismsWild Type MouseWorkcytokineimprovedintraperitonealmanmast cellmemory CD4 T lymphocyteoligodendrocyte-myelin glycoproteinprogramspromoterreceptorresponsesmall moleculetreatment strategytripolyphosphate
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Histamine, a mediator of inflammation and regulator of innate and adaptive immune responses, plays a significant role in the pathogenesis of experimental allergic encephalomyelitis (EAE), the principal autoimmune model of multiple sclerosis (MS). Histamine exerts its effect through four G-protein coupled receptors (GPCRs) designated histamine H1, H2, H3, and H4 receptor (H1R, H2R, H3R, and H4R). H1R is expressed in chronic MS plaques and MS patients receiving the H1R antagonist hydroxyzine remain stable or improve neurologically. Moreover, epidemiological data indicate that H1R antagonist use is associated with decreased MS risk. In MS and EAE histamine is viewed primarily as a mediator of inflammation due to its effect on the vasculature and blood brain barrier permeability. However, data in histamine- and histamine receptor- (HR) deficient mice indicate that histamine also plays a role in regulating encephalitogen-specific T-cell effector responses. We published that compared to wild-type mice, H1RKO mice develop less severe EAE and Th2-like anti-MOG35-55 CD4 T-cell responses. We now show that the H1R regulates IFN3 production by CD4 effector T-cells as a result of direct signaling during their initial activation. Additionally, we present data showing that all four HRs play a role in EAE. Moreover, in addition to expressing the H1R naive CD4 T-cells express the H2R and H4R but not the H3R, and upon activation down regulate the expression of all three HR types; however, CD4 memory T-cells gain expression of the H3R. Our overall working hypothesis is that direct HR signaling during activation of naive and memory CD4 T-cells regulates effector responses. In this application we propose to: 1) delineate the H1R signaling pathway regulating IFN3 secretion in CD4 T-cells and test the hypothesis that H1R signaling also regulates susceptibility to spontaneous EAE in (B6.TgTcrMOG W B6.TgIghMOG) F1 hybrid mice; 2) test the hypothesis that H2R and H4R signaling in naive CD4 T-cells directly regulate encephalitogen-specific T-cell effector responses, and 3) test the hypothesis that H3R signaling regulates MOG35-55-specific CD4 memory T-cell responses. Delineating the CD4 effector T-cell responses regulated by HRs in EAE may aid in the development of new strategies for the treatment of MS and modification of primary and anamnestic CD4 T-cell responses in general. In this regard, GPCRs are one of the most tractable set of targets for the development of clinically effective, small molecule pharmaceuticals. Of the drugs used clinically in man ~50% target GPCRs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
p38 MAPK as a female-specific druggable target in CNS autoimmune disease
-
批准号:8286179
-
项目类别:
-
资助金额:$19.06万
-
财政年份:2011
-
负责人:CORY TEUSCHER
-
依托单位:
p38 MAPK as a female-specific druggable target in CNS autoimmune disease
-
批准号:8205151
-
项目类别:
-
资助金额:$22.88万
-
财政年份:2011
-
负责人:CORY TEUSCHER
-
依托单位:
H1R Signaling and Immune Deviation in EAE
-
批准号:8415527
-
项目类别:
-
资助金额:$31.67万
-
财政年份:2010
-
负责人:CORY TEUSCHER
-
依托单位:
H1R Signaling and Immune Deviation in EAE
-
批准号:8015313
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2010
-
负责人:CORY TEUSCHER
-
依托单位:
H1R Signaling and Immune Deviation in EAE
-
批准号:7852561
-
项目类别:
-
资助金额:$34.26万
-
财政年份:2010
-
负责人:CORY TEUSCHER
-
依托单位:
H1R Signaling and Immune Deviation in EAE
-
批准号:8602861
-
项目类别:
-
资助金额:$32.49万
-
财政年份:2010
-
负责人:CORY TEUSCHER
-
依托单位:
H1R Signaling and Immune Deviation in EAE
-
批准号:8204523
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2010
-
负责人:CORY TEUSCHER
-
依托单位:
Sex Chromosomes in Fetal Programming and Susceptibility to EAE
-
批准号:7533009
-
项目类别:
-
资助金额:$46.68万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Sex Chromosomes in Fetal Programming and Susceptibility to EAE
-
批准号:7877725
-
项目类别:
-
资助金额:$45.45万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Histamine Receptor Signaling in CNS Autoimmune Disease
-
批准号:7359486
-
项目类别:
-
资助金额:$62.57万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Sex Chromosomes in Fetal Programming and Susceptibility to EAE
-
批准号:7629016
-
项目类别:
-
资助金额:$44.57万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Histamine Receptor Signaling in CNS Autoimmune Disease
-
批准号:7555068
-
项目类别:
-
资助金额:$62.06万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Histamine Receptor Signaling in CNS Autoimmune Disease
-
批准号:8204521
-
项目类别:
-
资助金额:$60.63万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Histamine Receptor Signaling in CNS Autoimmune Disease
-
批准号:7751201
-
项目类别:
-
资助金额:$62.21万
-
财政年份:2008
-
负责人:CORY TEUSCHER
-
依托单位:
Genetics of Suscptibility to Anthrax Toxin in vivo
-
批准号:6862597
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2004
-
负责人:CORY TEUSCHER
-
依托单位:
Genetics of Suscptibility to Anthrax Toxin in vivo
-
批准号:7018509
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2004
-
负责人:CORY TEUSCHER
-
依托单位:
Genetics of Suscptibility to Anthrax Toxin in vivo
-
批准号:7196479
-
项目类别:
-
资助金额:$35.91万
-
财政年份:2004
-
负责人:CORY TEUSCHER
-
依托单位:
Genetics of Suscptibility to Anthrax Toxin in vivo
-
批准号:7373608
-
项目类别:
-
资助金额:$35.23万
-
财政年份:2004
-
负责人:CORY TEUSCHER
-
依托单位:
Genetics of Suscptibility to Anthrax Toxin in vivo
-
批准号:6712568
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2004
-
负责人:CORY TEUSCHER
-
依托单位:
IMMUNOREGULATORY LOCI IN ORGAN SPECIFIC AUTOIMMUNITY
-
批准号:6594959
-
项目类别:
-
资助金额:$16.8万
-
财政年份:1999
-
负责人:CORY TEUSCHER
-
依托单位:
海外基金